Endo parent company changes name to Endo Health Solutions Inc.
CHADDS FORD, Pa. — The parent company of Endo Pharmaceuticals has changed its name, the company said.
Shareholders of Endo Pharmaceutical Holdings voted at the company’s annual shareholder meeting Wednesday to change the company’s name to Endo Health Solutions. The company said the name change would more accurately reflect its new business model, which aggregates four operating businesses into one enterprise.
"This important decision by our shareholders marks a milestone in our company’s history and reinforces our position in the market as a leading provider of health solutions, merging healthcare information and a broader array of innovative treatment options that can ultimately lead to improved health outcomes for patients," Endo president and CEO Dave Holveck said.
The company’s new business model will include four segments: medical device developer AMS; branded drug division Endo Pharmaceuticals; medical services, software, laboratory and medical records technology provider HealthTronics; and generic drug maker Qualitest.
Rexam teams up with Marsh, MainStreet Market pharmacies to offer safe Rx disposal
PERRYSBURG, Ohio — Rexam Prescription Products recently partnered with Marsh and MainStreet Market pharmacies for a new campaign that encourages consumers to safely dispose of their unused or expired medications.
The "Clean Out Your Medicine Cabinet" campaign encouraged consumers could bring their leftover medications to one of 40 Marsh Pharmacy and MainStreet Market Pharmacy locations throughout Indiana for free and safe disposal. More than 37,000 vials were collected over a 4-day period and were properly disposed through a local incinerator. Marsh first began hosting "clean out" events in 2008, and since that time has collected more than 140,000 vials of unused medications.
"We are pleased to partner with Marsh and support their efforts to improve prescription disposal," said Pat O’Connell, Rexam’s VP sales and marketing for prescription products. “It’s another example of how we work closely with our customers to address industry issues and add value to consumers’ lives."
Lilly, BI diabetes drug shows greater A1C reduction in African-American adults than placebo, study shows
RIDGEFIELD, Conn. — A drug used to treat Type 2 diabetes produced significant reduction in blood sugar in African-American patients, according to results of a late-stage clinical trial.
Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced Thursday results of a phase-3 trial of Tradjenta (linagliptin) in which 226 patients with Type 2 diabetes received 5 mg of the drug once per day or placebo.
Patients in the treatment group showed a reduction of HbA1C of 0.88%, compared with 0.24% among those receiving placebo. The drug makers noted that African Americans and other ethnic minority groups "significantly" are underrepresented in clinical trials, and this was the first published trial of a DPP-4 inhibitor — the drug class to which Tradjenta belongs — specifically conducted in African-American adult patients. Diabetes disproportionately affects African-Americans, with non-Hispanic African-American adults having a risk of developing the disease 77% greater than non-Hispanic white adults, according to the Centers for Disease Control and Prevention.